AstraZeneca Atacand HCT
This article was originally published in Pharmaceutical Approvals Monthly
FDA clears combination of the angiotensin-2 receptor antagonist candesartan and the diuretic hydrochlorothiazide Sept. 5 for second-line treatment of hypertension. Candesartan is marketed without hydrochlorothiazide as Atacand
You may also be interested in...
The blockbuster drug is expected to see overall sales declines in the next few years, and biosimilar competition could come as soon as 2023.
Plus deals involving WuXi AppTec/OXGENE, Oscotec/Beatica, ReViral/LianBio, Wugen/HCW Biologics, Starton/Haisco, Shanghai Junshi/AstraZeneca, HitGen/Uppthera, Bridge/LegoChem, Macrogen/Lifex, BeiGene/Boston Immune